Spain Animal Healthcare Market Trends and Insights
Rising Pet Ownership & Humanisation
In 2024, Spain's pet population reached 9.46 million dogs and 5.95 million cats, with 49% of households owning at least one pet and 39% of owners identifying as "pet parents." Increased attachment is evident as 74% of pet owners include pets in family photos and 71% purchase holiday gifts, driving demand for vaccines, parasiticides, and diagnostics. Pet-related spending is projected to hit EUR 3.8 billion (USD 4.18 billion) by 2030, with urban households favoring premium products and frequent clinic visits. Preferences lean towards palatable chews and combination parasiticides, while lighter regulatory pathways for companion products accelerate innovation cycles.EU "One-Health" Regulation Stimulating Preventive Care
EU Regulation 2019/6, implemented through Spanish Royal Decree 1157/2021, restricts prophylactic antimicrobial use and enforces stricter prescribing standards, redirecting budgets to vaccinations and diagnostics. By 2024, Spain reduced livestock antibiotic use by 70%, the highest in the EU, boosting vaccine adoption and alternatives to critical antimicrobials. Producers must now identify pathogens before accessing restricted classes, increasing demand for rapid tests and PCR panels. Compliance costs challenge smallholders, while integrated producers benefit from economies of scale. Non-compliance penalties push preventive strategies as standard practice, aligning the market with vaccines and diagnostics.Veterinarian Shortage, Particularly in Rural Spain
In 2024, Spain reported 37,836 registered veterinarians, yet rural areas face persistent staffing shortages relative to livestock populations. This gap delays treatments and increases reliance on non-specialist labor. New graduates prefer urban areas due to better compensation and predictable schedules, while rural livestock roles struggle to compete. Consolidators attract young veterinarians with salaried roles and centralized support, further concentrating talent in urban clinics. The shortage impacts the economy, as delayed disease diagnoses can lead to movement restrictions and reduced farm revenues, as seen during the lumpy skin disease outbreak in Catalonia. Government proposals for mandatory rural service were withdrawn after objections, and alternatives like telemedicine and mobile units have not fully replaced hands-on care. This structural gap hinders disease control and modernization for smallholder farms lacking resources to standardize protocols.Other drivers and restraints analyzed in the detailed report include:
- Technological Advances in Point-of-Care Diagnostics
- Growing Pet-Insurance Penetration Enabling Spend
- High Cost of Advanced Therapeutics & Diagnostics
Segment Analysis
In 2025, therapeutics dominated Spain's animal healthcare market with a 64.6% share, but diagnostics are projected to grow at an 11.5% CAGR through 2031, outpacing the baseline. Vaccines remain central to therapeutics, driven by national programs targeting diseases such as bovine tuberculosis and brucellosis, ensuring predictable purchasing and adherence to protocols. Subsidized vaccine campaigns enhance herd immunity and reduce reliance on antimicrobials. Parasiticides, particularly isoxazoline combinations, are gaining traction due to their broad-spectrum coverage and ease of administration, aligning with urban pet owners' preferences. Anti-infectives remain vital for specific cases, though diagnostics-first policies are increasingly emphasized in livestock. Diagnostics are advancing as clinics adopt in-house platforms delivering rapid results, enabling same-visit treatments and boosting client satisfaction. In livestock, tools like PCR screening and rapid tests help detect pathogens early, reducing depopulation costs. This shift toward diagnostics is driving sustained growth despite price sensitivity, as clinics embed point-of-care workflows.In 2025, companion animals accounted for 58.5% of Spain's animal healthcare market, growing at a 10.2% CAGR, supported by urban ownership rates and increased spending on diagnostics, vaccines, and preventive care. Cats are the fastest-growing sub-segment, driven by the 2024 launch of feline-specific vaccines. Policy stability and lighter regulations enable premium pricing through formulation upgrades, while rising insurance penetration supports higher-ticket procedures. Livestock is projected to grow faster at an 11.8% CAGR through 2031, as producers prioritize biosecurity to protect exports and productivity. Spain's leadership in pig production and ruminant herds ensures steady demand for vaccines and diagnostics, supported by digital platforms consolidating health data for better oversight. Recent disease outbreaks highlight the importance of early detection and prevention-first strategies, which are driving livestock growth dynamics alongside companion demand.
Complete Report Scope:
- By Product
- Therapeutics
- Vaccines
- Parasiticides
- Anti-infectives
- Medical Feed Additives
- Other Therapeutics
- Diagnostics
- Immunodiagnostic Tests
- Molecular Diagnostics
- Diagnostic Imaging
- Clinical Chemistry
- Other Diagnostics
- Therapeutics
- By Animal Type
- Companion Animals
- Dogs
- Cats
- Other Companion Animals
- Livestock Animals
- Ruminants (Cattle, Sheep, Goats)
- Swine
- Poultry
- Other Livestock Animals
- Companion Animals
- By Route of Administration
- Oral
- Parenteral (Injectables)
- Topical
- Others
- By Distribution Channel
- Veterinary Clinics & Hospitals
- Retail Pharmacies
- Online Pharmacies & e-Commerce
- On-Farm / Direct Supply
List of Companies Covered in this Report:
- Bioiberica
- BioVet SA
- Boehringer Ingelheim
- Ceva
- Dechra Pharmaceuticals Inc.
- Elanco
- Hipra
- IDEXX
- Laboratorios Eurisko
- Laboratorios Karizoo
- Laboratorios Syva
- MSD Animal Health (Merck)
- Neogen
- S.P. Veterinaria
- Super's Diana S.L.
- Vetoquinol
- Virbac
- Zoetis
- Zoopan
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bioiberica S.A.U.
- BioVet SA
- Boehringer Ingelheim GmbH
- Ceva Sante Animale
- Dechra Pharmaceuticals Inc.
- Elanco Animal Health
- HIPRA
- IDEXX Laboratories
- Laboratorios Eurisko
- Laboratorios Karizoo
- Laboratorios Syva
- MSD Animal Health (Merck)
- Neogen Corporation
- S.P. Veterinaria
- Super's Diana S.L.
- Vetoquinol SA
- Virbac
- Zoetis Inc.
- Zoopan

